Sun Pharma is the biggest loser on the Nifty as it missed estimates. Also, the management gave a very conservative guidance of 8-10 percent growth in consolidated sales for FY17. A bullish SP Tulsian of sptulsian.com gave a support price of Rs 700.
first published: May 31, 2016 03:47 pm
A collection of the most-viewed Moneycontrol videos.
Live: Will Nifty continue its rangebound move this week? | Opening Bell
The Lawyer Renting in a 120-year-old building in South Mumbai | The Tenant
Nifty On Track To End Week Above 25,500 As Bank & Metal Stocks Lead Rebound| Closing Bell Live
Can Nifty Stage A Friday Fightback After Hitting 3-Week Low? Pine Labs IPO Opens | Opening Bell Live
